Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology

Managing the Acute Attack: Emergency Treatments

At a Glance

An acute Baló concentric sclerosis attack is treated urgently with specialist-directed high-dose IV methylprednisolone. If steroids are not enough, plasma exchange may be used, while severe refractory cases may require cyclophosphamide with close monitoring for serious risks.

When Balo’s Concentric Sclerosis (BCS) is in its active, acute phase, the goal of treatment is to stop the immune system’s attack on your brain as quickly as possible. Because the lesions in BCS can be large and cause significant swelling, doctors treat an acute attack as a medical priority to prevent further damage to the myelin and underlying nerve fibers [1][2]. There is no validated BCS-specific escalation algorithm, so these examples represent specialist-directed, often off-label practices extrapolated from other inflammatory demyelinating diseases.

Safety Warning: Do not start, stop, or change doses of steroids or immune therapies without your doctor’s explicit instruction. Report any new fever, marked high blood sugar, severe mood or sleep changes, allergic symptoms, or severe abdominal pain to your care team immediately.

High-Dose Steroids

A common initial therapy for an acute BCS attack is Intravenous Methylprednisolone (often called “solu-medrol”). This is a powerful anti-inflammatory medication delivered through an IV.

  • The Regimen: Doctors typically prescribe a “pulse” of 1,000 mg (1 gram) per day for 3 to 5 days, though the exact dose, duration, and taper are individualized [3][4]. In children, the dose is often calculated by weight, such as 30 mg/kg per day [5].
  • How It Works: These steroids work by rapidly reducing inflammation and stabilizing the Blood-Brain Barrier (the protective shield that prevents immune cells from entering the brain). This helps to decrease the swelling (edema) around the “onion-skin” lesions [1][6].
  • Response Rates: While many patients show improvement within 24 to 48 hours, response rates can vary. In one large study, about 46% of BCS patients showed a clear clinical response to steroids alone [1][7].

Plasma Exchange (PLEX)

If high-dose steroids do not sufficiently improve your symptoms or if the attack is exceptionally severe, your care team may consider Plasma Exchange (also called Plasmapheresis or PLEX).

  • The Process: This treatment is like “filtering” your blood. Your blood is cycled through a machine that removes the liquid portion (plasma), which contains the harmful antibodies and proteins attacking your brain. This plasma is then replaced with a substitute (usually albumin) and returned to your body [8][9].
  • The Schedule: A typical course may involve five separate exchange sessions, usually performed every other day over a period of 8 to 10 days, though this is heavily individualized [9][3].
  • Effectiveness and Risks: PLEX can be highly effective when steroids fail. In some cases, patients have seen significant recovery from severe symptoms, such as difficulty swallowing or weakness, after starting PLEX [10][11]. However, PLEX carries risks such as low blood pressure (hypotension), bleeding or clotting problems, allergic reactions to the fluid, and infection at the vascular-access catheter site.

Intense Immunosuppression

For cases that are “refractory” (meaning they do not respond to steroids or plasma exchange), doctors may use high-dose immunosuppressive agents like Cyclophosphamide.

  • How It Works: This is a powerful immunosuppressant that more aggressively “shuts down” the immune cells responsible for the attack. It is often reserved for severe cases because it has more significant side effects, though it is not a universal third-line treatment [12][13].
  • Key Goals and Severe Risks: The primary aim is to halt the expansion of the concentric rings and allow the brain to begin the healing process. While cyclophosphamide is often effective in these dire situations, it requires careful monitoring. You must discuss serious risks with your doctor, including life-threatening infection, infertility or gonadal failure (requiring fertility-preservation planning), teratogenicity, severe bladder bleeding (hemorrhagic cystitis), and later malignancy risk [14][15].

What to Expect During Acute Treatment

These treatments are intense, and your medical team will monitor you closely in the hospital for side effects. Common experiences include:

  • Steroid Side Effects: You may feel anxious, have trouble sleeping (insomnia), or notice a metallic taste in your mouth. Steroids can also temporarily raise your blood sugar and blood pressure [16][6][17]. Check your blood sugar regularly if instructed.
  • PLEX Monitoring: During plasma exchange, the team will monitor your calcium levels and electrolytes, as the process can cause temporary imbalances that might make you feel tingly or dizzy [18][19].
  • Response Timing: Recovery is rarely instantaneous. While the “attack” is halted quickly, the nerves need time to heal. Your doctors will use follow-up MRIs to confirm the inflammation is subsiding, and worsening symptoms require urgent reassessment [1][20].

Common questions in this guide

What is usually given first for an acute Baló concentric sclerosis attack?
Doctors commonly start with high-dose intravenous methylprednisolone, a corticosteroid given through a vein to reduce inflammation and swelling in the brain. The dose and duration are individualized, and treatment should be directed by the specialist team.
What happens if steroids do not improve my BCS symptoms?
If symptoms remain severe or do not improve enough after high-dose steroids, the care team may consider plasma exchange, also called PLEX or plasmapheresis. It removes and replaces the liquid part of the blood and is usually performed as a series of hospital sessions.
How long does plasma exchange take for Baló concentric sclerosis?
A typical course may involve about five exchange sessions every other day over 8 to 10 days, but the schedule is individualized. Teams monitor blood pressure, calcium, and electrolytes because plasma exchange can cause low blood pressure or temporary imbalances.
When might cyclophosphamide be used for BCS?
Cyclophosphamide may be considered when a severe attack does not respond adequately to steroids or plasma exchange. It is a powerful immune-suppressing medicine and requires close monitoring because it can cause serious infection, fertility problems, bladder bleeding, pregnancy-related harm, and a later cancer risk.
What side effects can high-dose steroids cause during acute BCS treatment?
High-dose steroids can cause trouble sleeping, anxiety or feeling unusually energized, a metallic taste, and temporary increases in blood sugar and blood pressure. Tell the care team about severe mood or sleep changes, fever, or other concerning symptoms rather than changing the medicine yourself.
How will doctors know whether treatment is working?
Recovery may not be immediate because the nerves need time to heal even after the immune attack is controlled. Doctors monitor symptoms in the hospital and use follow-up MRI scans to check whether inflammation and swelling are subsiding; worsening symptoms need urgent reassessment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my MRI, how soon should we start the IV methylprednisolone, and what is the exact daily dose and duration you are planning?
  2. 2.If my symptoms do not improve within the first 48 to 72 hours of steroids, what is your threshold for starting plasma exchange (PLEX)?
  3. 3.Are you monitoring my blood glucose, heart rate, and electrolytes daily while I am on high-dose steroids?
  4. 4.If we have to escalate to cyclophosphamide, what are the risks for my long-term fertility, and are there steps we should take now to protect it?
  5. 5.What is the specific plan for monitoring for signs of infection or bladder irritation while I am receiving these intense treatments?
  6. 6.If I require plasma exchange, will I need a central line (a large IV in my neck or chest), or can we use my peripheral veins?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Clinical and Radiologic Features, Pathology, and Treatment of Baló Concentric Sclerosis.

    Jolliffe EA, Guo Y, Hardy TA, et al.

    Neurology 2021; (97(4)):e414-e422 doi:10.1212/WNL.0000000000012230.

    PMID: 34011576
  2. 2

    Baló's concentric sclerosis - A rare entity within the spectrum of demyelinating diseases.

    Xie JS, Jeeva-Patel T, Margolin E

    Journal of the neurological sciences 2021; (428()):117570 doi:10.1016/j.jns.2021.117570.

    PMID: 34261000
  3. 3

    Visual Function Improvement after Plasma Exchange Therapy for Acute Optic Neuritis in Neuromyelitis Optica Spectrum Disorders: Case Series and Review.

    Iancu R, Pirvulescu R, Anton N, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(9)) doi:10.3390/diagnostics14090863.

    PMID: 38732279
  4. 4

    Optic neuritis: a comprehensive review of current therapies and emerging treatment strategies.

    Chaitanuwong P, Moss HE

    Frontiers in neurology 2025; (16()):1605075 doi:10.3389/fneur.2025.1605075.

    PMID: 40606143
  5. 5

    Balo's concentric sclerosis: An atypical demyelinating disease in pediatrics.

    Arenas Vargas LE, Bedoya Morales AM, Rincón Carreño C, et al.

    Multiple sclerosis and related disorders 2020; (44()):102198 doi:10.1016/j.msard.2020.102198.

    PMID: 32531753
  6. 6

    Characteristics of adverse drug reactions and risk management strategies for methylprednisolone sodium succinate in the treatment of idiopathic sudden sensorineural hearing loss: a clinical study of 1026 patients.

    Wu T, Tang Y, Yan S, et al.

    Frontiers in medicine 2025; (12()):1589531 doi:10.3389/fmed.2025.1589531.

    PMID: 40568206
  7. 7

    A Rare Case of Balo Concentric Sclerosis, a Subtype of Tumefactive Multiple Sclerosis, in a 40-Year-Old Male: Case Report.

    Al Ashi AK, Meray V, Aziz AM

    Cureus 2022; (14(4)):e24033 doi:10.7759/cureus.24033.

    PMID: 35547427
  8. 8

    Plasma exchange in inflammatory demyelinating disorders of the central nervous system: reasonable use in the clinical practice.

    Queiroz ALG, Soares Neto HR, Kobayashi TT, Silva SMCA

    Arquivos de neuro-psiquiatria 2023; (81(3)):296-307 doi:10.1055/s-0042-1758447.

    PMID: 37059439
  9. 9

    Therapeutic Efficacy of Plasma Exchange in Neuromyelitis Optica.

    Kumar R, Paul BS, Singh G, Kaur A

    Annals of Indian Academy of Neurology 2018; (21(2)):140-143 doi:10.4103/aian.AIAN_330_17.

    PMID: 30122840
  10. 10

    Bilateral optic neuritis preceding a Baló concentric sclerosis lesion: A case report and literature review.

    Alfonso-Cedeño DF, Medina-Lozano L, Gaete PV, Quintero-Cusguen P

    Journal of neuroimmunology 2026; (413()):578874 doi:10.1016/j.jneuroim.2026.578874.

    PMID: 41619449
  11. 11

    Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.

    Chico-Garcia JL, Morales de la Prida M, Boix Lago A, et al.

    Therapeutic advances in neurological disorders 2026; (19()):17562864261440665 doi:10.1177/17562864261440665.

    PMID: 42137633
  12. 12

    Heterogeneity of Baló's concentric sclerosis: a study of eight cases with different therapeutic concepts.

    Tzanetakos D, Vakrakou AG, Tzartos JS, et al.

    BMC neurology 2020; (20(1)):400 doi:10.1186/s12883-020-01971-2.

    PMID: 33138795
  13. 13

    Pediatric tumefactive multiple sclerosis case (with baló-like lesions), diagnostic and treatment challenges.

    Kamari C, Galanakis E, Raissaki M, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(1)):343-345 doi:10.1007/s10072-022-06396-y.

    PMID: 36171523
  14. 14

    Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review.

    Teles KA, Medeiros-Souza P, Lima FAC, et al.

    Revista brasileira de reumatologia 2017; (57(6)):596-604 doi:10.1016/j.rbre.2016.09.008.

    PMID: 29173694
  15. 15

    Position statement of the Brazilian society of Rheumatology on mesna use as a preventive therapy for bladder disease in patients with systemic autoimmune diseases and systemic vasculitis under cyclophosphamide treatment.

    Souza AWS, Dantas JG, Montandon ACOES, et al.

    Advances in rheumatology (London, England) 2024; (64(1)):41 doi:10.1186/s42358-024-00380-0.

    PMID: 38773538
  16. 16

    Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial.

    Berkovich R, Bakshi R, Amezcua L, et al.

    Therapeutic advances in neurological disorders 2017; (10(1)):3-17 doi:10.1177/1756285616670060.

    PMID: 28450891
  17. 17

    Acute Symptomatic Sinus Bradycardia in High-Dose Methylprednisolone Therapy in a Woman With Inflammatory Myelitis: A Case Report and Review of the Literature.

    Sodero A, Squitieri M, Mazzeo S, et al.

    Clinical medicine insights. Case reports 2019; (12()):1179547619831026 doi:10.1177/1179547619831026.

    PMID: 30828250
  18. 18

    Early clinical response and complications of therapeutic plasma exchange in central nervous system demyelinating diseases.

    Rashidi M, Naghavi S, Ramezani N, et al.

    Journal of central nervous system disease 2024; (16()):11795735241262738 doi:10.1177/11795735241262738.

    PMID: 38903856
  19. 19

    Therapeutic plasma exchange (TPE) for semi-critical neurology presentations in a non-acute neurology set-up: clinical practice and challenges.

    Fu KS, Wong PY, Hiew FL

    BMJ neurology open 2020; (2(1)):e000020 doi:10.1136/bmjno-2019-000020.

    PMID: 33681775
  20. 20

    Baló's concentric sclerosis: A retrospective case series.

    Peraza H, Rees J, Kresak J, et al.

    Multiple sclerosis and related disorders 2025; (103()):106712 doi:10.1016/j.msard.2025.106712.

    PMID: 40946697

This page explains emergency treatments for an acute Baló concentric sclerosis attack for informational purposes only and does not constitute medical advice. Your neurology team should guide medication choices, monitoring, and any treatment escalation.

Get notified when new evidence is published on Baló concentric sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.